| Company: | Vertex Pharmaceuticals |
| Ticker Symbol: | VRTX |
| Class Period: | May-7-12 to May-29-12 |
| Date Filed: | Jul-2-14 |
| Lead Plaintiff Deadline: | Aug-31-14 |
| Court: | District of Massachusetts |
| Allegations: | |
Vertex is engaged in discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. The Company markets Kalydeco in the United States and European Union as a treatment for patients aged six years and older with a rare form of cystic fibrosis. The Complaint alleges that the Company issued false and misleading public statements concerning Vertex's products VX-809 and Kalydeco.
On May 29, 2012, the Company issued a correction of the interim analysis of the Phase 2 Combination Study of VX-809 and Kalydeco, stating that the correction was due to a "misinterpretation" between Vertex and a third-party statistical analysis vendor over the study data. Following this news, the Company's stock price plummeted from its previous closing price of $64.85 on May 25, 2012, to close at $57.80 per share on May 29, 2012.
If you acquired the securities of the defendants during the Class Period you may, no later than the Lead Plaintiff Deadline shown above, request that the Court appoint you as lead plaintiff through counsel of your choice. You may also choose to remain an absent class member. A lead plaintiff must meet certain requirements.
